Researchers conducted retrospective multicenter analysis of patients diagnosed with acute myeloid leukemia or myelodysplastic syndromes who had hematological relapse after allogeneic hematopoietic stem cell transplantation and were treated with azacitidine for this indication.
[European Journal of Haematology]
Drozd‐Sokołowska, J., Karakulska‐Prystupiuk, E., Biecek, P., Kobylińska, K., Piekarska, A., Dutka, M., Waszczuk‐Gajda, A., Mądry, K., Kopińska, A., Gołos, A., Góra‐Tybor, J., Szwedyk, P., Bołkun, Ł., Czyż, A., Giebel, S., Basak, G. W., & Dwilewicz‐Trojaczek, J. (n.d.). Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis. European Journal of Haematology, n/a(n/a). https://doi.org/https://doi.org/10.1111/ejh.13628 Cite
0